Quantcast

Identification of a cell line producing high levels of TSLP: advantages for screening of anti-allergic drugs.

Research paper by Ryosuke R Segawa, Saori S Yamashita, Natsumi N Mizuno, Mika M Shiraki, Takahiro T Hatayama, Nozomi N Satou, Masahiro M Hiratsuka, Michihiro M Hide, Noriyasu N Hirasawa

Indexed on: 21 Nov '13Published on: 21 Nov '13Published in: Journal of Immunological Methods



Abstract

Thymic stromal lymphopoietin (TSLP) plays critical roles in the induction and exacerbation of allergic diseases. These findings suggest that an inhibitor of TSLP production may be a novel drug for allergic diseases. However, conducting high-throughput screening of such compounds is difficult because there is currently no appropriate in vitro system. In the present study, we demonstrated that the mouse keratinocyte cell line KCMH-1 produced higher amounts of TSLP than the mouse keratinocyte cell line PAM-212, human keratinocyte cell line HaCaT, or bronchial cell line BEAS-2B. A reporter gene assay revealed that transcriptional activity of the TSLP gene was also markedly higher in KCMH-1 than in PAM212 cells. Both dexamethasone and the retinoid X receptor agonist HX600 inhibited the production of TSLP in KCMH-1 cells, which indicated that its production could be pharmacologically regulated. Moreover, the biological activity of TSLP released from KCMH-1 cells in the medium was endorsed by the induction of OX40L expression in bone marrow-derived dendritic cells. These results indicate that KCMH-1 can be utilized in high-throughput screening of inhibitors of TSLP production and also as a source of native TSLP.